Advertisement

Topics

Update: French Red Blood Cell Biotech Aims Higher for $125M Nasdaq IPO

08:20 EST 10 Nov 2017 | Labiotech.eu

Update: Erytech has upgraded its projected IPO to $125M by offering more shares than originally planned. Originally published 09/10/2017 Erytech has filed for an IPO on the Nasdaq Global Market and a private placement on Euronext Paris while preparing for ...

This awesome article Update: French Red Blood Cell Biotech Aims Higher for $125M Nasdaq IPO appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Update: French Red Blood Cell Biotech Aims Higher for $125M Nasdaq IPO

NEXT ARTICLE

More From BioPortfolio on "Update: French Red Blood Cell Biotech Aims Higher for $125M Nasdaq IPO"

Advertisement
Quick Search
Advertisement
Advertisement